8-K 1 v097965_8k.htm Unassociated Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 20, 2007

CYTOMEDIX, INC.
(Exact name of registrant as it appears in its charter)
 
Delaware
 001-32518
 23-3011702  
(State or other jurisdiction  
of incorporation)
 (Commission
File Number)
 (IRS Employer
Identification No.)
                                       
416 Hungerford Drive, Suite 330
Rockville, Maryland 20850
(Address of principal executive offices and zip code)

240-499-2680
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 

Section 8 - Other Events

Item 8.01. Other Events

On December 20, 2007, Cytomedix issued the press release attached as Exhibit 99.1 announcing that the Centers for Medicare and Medicaid Services (“CMS”) has reaffirmed its 2003 national non-coverage decision for autologous blood derived products for chronic non-healing wounds in a draft response to a national coverage reconsideration requested by Cytomedix. The proposed decision memorandum can be viewed in its entirety at https://www.cms.hhs.gov/mcd/viewdraftdecisionmemo.asp?id=208.

Cytomedix will hold a conference call with members of the investment community at 1:00 p.m., eastern standard time, Friday, December 21, 2007, to discuss the CMS proposed decision and other company developments. To participate, interested parties should dial 1-877-407-8035 approximately 10 minutes before the conference call is scheduled to begin. Hold for the operator and reference the Cytomedix, Inc. conference call. International callers should dial 201-689-8035.

Access to a recording will also be available for seven days following the conference call. Dial 1-877-660-6853 to access playback. For international callers, dial 201-612-7415. Enter account number 286. The pass code I.D. is 267277.

The press release announcing the conference call is attached as Exhibit 99.2.

Section 9 - Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

(c) Exhibits. The following Exhibits are furnished with this Current Report on Form 8-K:

Exhibit No.   Description
Exhibit 99.1   Press Release of Cytomedix, Inc., dated December 20, 2007.
Exhibit 99.2   Press Release of Cytomedix, Inc., dated December 21, 2007.
 
 
 
 

 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
  CYTOMEDIX, INC.
 
 		  
 		  
 
Date: December 21, 2007 By:   /s/ Andrew S. Maslan 
 
Andrew S. Maslan
Chief Financial Officer